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Abstract Previously, we cloned rat MRP3 as a candidate for an
inducible transporter for the biliary excretion of organic anions
[Hirohashi et al. (1998) Mol. Pharmacol. 53, 1068^1075]. In the
present study, we cloned human MRP3 (1527 amino acids) from
Caco-2 cells. Human MRP3 is predominantly expressed in liver,
small intestine and colon; hepatic expression of MRP3 was
observed in humans but not in normal rats. In HepG2 cells, the
expression of MRP3 was induced by phenobarbital. These results
suggest that MRP3 may act as an inducible transporter in the
biliary and intestinal excretion of organic anions.
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1. Introduction
Many organic anions including conjugated metabolites are
excreted into the bile across the bile canalicular membrane via
a primary active transporter referred to as the canalicular
multispeci¢c organic anion transporter (cMOAT/multidrug
resistance associated protein 2 (MRP2)) [1^7], a member of
the GS-X pump family [8^10]. The substrate speci¢city of
cMOAT/MRP2 has been examined by comparing the trans-
port properties across the bile canalicular membrane using
normal and mutant rats (such as TR3 and Eisai hyperbiliru-
binemic rats (EHBR)) whose cMOAT/MRP2 function is he-
reditarily defective [1^7]. These mutant rats su¡er from jaun-
dice due to the impaired biliary excretion of bilirubin
glucuronide via cMOAT/MRP2 and, therefore, are a good
animal model for Dubin-Johnson syndrome in humans [1^
7]. Recently, we and others have cloned rat and human
cMOAT/MRP2 cDNA based on the homology with human
MRP1 [11^15], and have clari¢ed the mechanism for the mu-
tation in mutant rats and patients su¡ering from Dubin-John-
son syndrome [11,14,16,17]. In addition, functional analysis of
the cloned cDNA product has been performed [15,18^20].
However, kinetic studies with isolated bile canalicular mem-
brane vesicles (CMVs) suggested the presence of multiple
transport systems for the biliary excretion of organic anions
and conjugated metabolites across the bile canalicular mem-
brane [21,22]. As candidate molecules for the putative trans-
porter(s), we have recently cloned two additional transporters
referred to as MRP-like protein (MLP) 1 and 2 [23]. Sequence
alignment indicated that MLP2 is the rat homologue of hu-
man MRP3 located on chromosome 17 [23,24]. Northern blot
analysis indicated that MLP1 is predominantly expressed in
the liver of both SD rats and EHBR, whereas hepatic expres-
sion of MRP3 is observed only in EHBR [23]. In addition,
MRP3 is markedly induced in Sprague-Dawley rat liver by
treatments which elevated the plasma concentration of biliru-
bin or bilirubin glucuronide, and by phenobarbital (PB) [25].
Although the full sequence of human MRP1, cMOAT/MRP2
and 5 has been reported [13,16,26^28], only a partial sequence
is available for MRP3 [24,29]. The purpose of the present
study was to clone the full length of human MRP3 and to
examine its expression in order to investigate the possible
involvement of this transporter in the biliary excretion of or-
ganic anions.
2. Materials and methods
2.1. Cell culture and RNA isolation
Total RNA was prepared from Caco-2 cells, HepG2 cells and hu-
man liver by a single-step guanidinium thiocyanate procedure. RNA
isolation from Caco-2 cells was performed at 0, 5, 7, 10 and 15 days
after becoming con£uent. In order to examine the inducibility of
MRP3 in HepG2 cells, 0, 1, 2 and 10 mM PB was added to the
medium 7 days after becoming con£uent. The HepG2 cells were re-
moved for isolation of RNA on day 10. A human liver specimen
(female Caucasian, 28 years old) was provided by SRI International
(Menlo Park, CA). Poly(A) RNA was puri¢ed using Oligotex-dT30
(Takara Shuzo, Kyoto, Japan).
2.2. Ampli¢cation of cDNA fragments and preparation of the
cDNA probe
cDNA fragments were ampli¢ed by RT-PCR according to the
method described previously [14,30] with total RNA of human liver
as a template using an RNA-PCR kit (Takara Shuzo). For PCR, the
degenerated primers were prepared on the basis of the conserved
amino acid sequence in the ABC region of human MRP1 [26,30].
The sequences of the forward and reverse primers were 5P-dGA-
GAAGGTGGGCATCGTGGG(AGTC)CG(AGTC)AC(AGTC)GG-
3P and 5P-dGTCCACGGCTGC(AGTC)GT(AGTC)GC(TC)TC(AG)-
TC-3P, respectively [30]. The ampli¢ed PCR product (421 bp) was
subcloned into the EcoRV site of pBluescript II SK3 (Stratagene,
La Jolla, CA) and the sequence was determined [30]. This 421 bp
cDNA fragment was used as the probe for Northern blot analysis
or library screening [30]. Northern blot analysis was performed ac-
cording to the method described previously [14,30] except that a Mul-
tiple Tissue Northern Blot (Clontech Laboratories, Palo Alto, CA)
was used to determine the expression in human tissues.
2.3. Library construction and screening
The cDNA library was constructed with a Lambda ZAP II vector
(SuperScript Choice System, Life Technologies, Gaithersburg, MD)
[14]. Packaging of recombinants into the V-phage was performed us-
ing a kit (Gigapack II Gold packaging Extract, Stratagene) [14]. After
two rounds of screening, single positive colonies were isolated. Fol-
lowing co-infection with the M13 helper phage (ExAssist, Stratagene),
the cDNA was excised in a pBluescript II SK3 plasmid and rescued
by SOLR strain [14].
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3. Results
3.1. Cloning of human MRP3 from Caco-2 cells
In order to clone human MRP3 cDNA, RT-PCR was per-
formed with degenerated primers using RNA from human
liver. The cDNA fragment with 421 bp was ampli¢ed and
its amino acid identity was 89.5% with rat MRP3, 68.7%
with human cMOAT/MRP2 and 72.4% with human MRP1.
Based on the high homology with rat MRP3, this fragment
was regarded as the partial sequence of human MRP3.
Since the quality of the human liver specimen was not good
enough to prepare a cDNA library, Caco-2 cells were chosen
as the source of mRNA, since Northern blot analysis showed
relatively high expression of human MRP3 in these cells cul-
tured for 10 days after becoming con£uent. A full-length
cDNA with an open reading frame of 1527 amino acid resi-
dues was cloned for human MRP3 with two highly conserved
ABC regions (Fig. 1). The identity of the amino acid sequence
of MRP3 between humans and rats was 82.5%. The pattern of
the hydropathy plot of MRP3, analyzed with the method by
Eisenberg et al. [31], resembles that of MRP1 and cMOAT/
MRP2 (Fig. 2). A BLAST search of the National Center for
Biotechnology Information database showed that, at deduced
amino acid levels, human MRP3 exhibits high overall identity
with several ABC proteins such as human MRP1 and
cMOAT/MRP2 (56.4% and 45.9%, respectively), rather than
human MDR1 (20.6%).
3.2. Tissue distribution of human MRP3
Northern blot analysis indicated that human MRP3 mRNA
is highly expressed in liver, colon, and small intestine, with
low expression in lung, spleen and kidney (Fig. 3). Although
the tissue expression pattern of MRP3 in humans resembles
that in rats, the liver was exceptional in that hepatic expres-
sion is observed in normal humans, but not in normal rats
(Fig. 3) [23]. To con¢rm the expression of MRP3 in human
liver, Northern blot analysis was performed using poly(A)
RNA (5 Wg) from another human liver specimen. The density
of the band was about one-third that of human cMOAT/
MRP2 (data not shown).
3.3. Induction of human MRP3 in HepG2 cells
Induction of human MRP3 was studied in HepG2 cells,
since this cell line has been widely used to study the induction
of metabolic enzymes such as P450 [32]. Northern blot anal-
ysis indicated that the expression of human MRP3 in HepG2
cells was enhanced by PB in a concentration-dependent man-
ner (Fig. 4). Moreover, expression of MRP1 and cMOAT/
MRP2 was also observed at higher PB concentrations (10
mM).
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Fig. 1. Deduced amino acid sequence of cloned human MRP3. The
nucleotide binding domains are indicated by an underline.
Fig. 2. Hydropathy plot of MRP family members. The pattern of
the hydropathy plot, analyzed with the method described by Eisen-
berg et al. [31], was compared in human MRP1, cMOAT/MRP2
and MRP3. ABC regions are indicated by a shadow.
Fig. 3. Tissue expression of MRP3. The expression of MRP3 in hu-
man tissues was examined by Northern blot analysis using Multiple
Tissue Northern Blot (Clontech Laboratories) with the 32P-labeled
carboxy-terminal ABC region.
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4. Discussion
Multiplicity of active e¥ux transport systems in rats has
been shown not only by kinetic studies using CMVs but
also using molecular biology techniques [22,23]. In normal
rat liver, cMOAT/MRP2 and MLP1 are expressed, whereas
in EHBR liver, MLP1 and MLP2 (MRP3) are expressed [23].
Moreover, hepatic expression of MRP3 in Spraque-Dawley
rats was induced by PB and by treatments which elevated
the plasma concentration of bilirubin and/or its glucuronide
[25]. In the present study, cloning of the human homologue of
rat MRP3 was performed to investigate the multiplicity of
biliary excretion. The alignment of the deduced amino acid
sequence (Fig. 1) and the hydropathy plot of human MRP3
(Fig. 2) revealed that this protein belongs to the MRP family
which may contain 17 transmembrane domains [33].
Extensive expression of human MRP3 was observed in liver
(see Section 3 and Fig. 3), which is in marked contrast to rats
[23], although this has not been established in general since
liver specimens from only two human subjects were examined.
It is possible that the expression of human MRP3 may have
been induced by many factors and, therefore, the expression
level of MRP3 may be involved in possible interindividual
di¡erences in biliary excretion. This hypothesis is supported
by the in vitro ¢nding that MRP3 was induced in HepG2 cells
(Fig. 4). Although CYP enzymes are also induced by PB in
vivo and also in HepG2 cells in vitro [32], the mechanism for
this induction is not necessarily the same for the two proteins.
Such an example has been reported for the hepatic induction
of mdr1 and CYP3A enzymes [34]. The inducers for both
proteins overlap, irrespective of the fact that the DNA bind-
ing proteins required for the induction are di¡erent [35].
In the present study, we could detect signi¢cant induction
of MRP1 and cMOAT/MRP2 by PB in HepG2 cells,
although a higher PB concentration was required than for
MRP3 (Fig. 3). This ¢nding is consistent with the previous
in vivo ¢nding that PB, at a dose of 80 mg/kg i.p. for 4 days,
could induce MRP3, but not MRP1 or cMOAT/MRP2 to a
signi¢cant level [25]. This inducible nature of some MRP fam-
ily members by chemical carcinogens and antineoplastic drugs
has been reported previously. Kau¡mann et al. [36] reported
the induction of cMOAT/MRP2, but not that of MRP1, in
cultured rat hepatocytes by cisplatin, 2-acetylamino£uorene
(AAF) and cycloheximide. Recently, they analyzed the 5P-
£anking region of rat cMOAT/MRP2 and showed that the
induction by AAF and probably by cisplatin is related to
the downstream of base 3250 in the £anking region, which
contains Sp1 and PEA3 regions [37]. Moreover, they reported
that the 5P-£anking region between bases 3581 and 3436 may
be necessary for the induction of this transporter by PB in a
rat hepatoma cell line, H4IIE [37]. Simultaneous induction of
MRP1, cMOAT/MRP2 and MRP3 has also been observed in
some doxorubicin-resistant non-small cell lung cancer cells
and in cisplatin-resistant colon carcinoma cells [24,29].
Although Ishikawa and his collaborators identi¢ed the factors
for the simultaneous induction of MRP1 and Q-glutamylcys-
teine synthetase, a rate determining enzyme for glutathione
synthesis [9], further studies of the promoter region of
MRP3 are required to determine the mechanism of induction.
The results of the present study may have some implications
for the transport properties in CMVs. We found that the
ATP-dependent uptake of glutathione conjugates and other
non-conjugated organic anions in CMVs from humans is 5^
10 times lower than that in rat CMVs, whereas the uptake of
glucuronide conjugates was comparable between the two spe-
cies [38]. This di¡erence could be accounted for not only by a
species di¡erence in the substrate-speci¢c transport character-
istics of cMOAT/MRP2, but also by a di¡erence in the pop-
ulation of transporters expressed on the bile canalicular mem-
brane, i.e. if it is assumed that the ability of human cMOAT/
MRP2 to transport all ligands examined previously is lower
than that of rat cMOAT/MRP2, the species di¡erence in the
transport activity in CMVs can be accounted for by the hy-
pothesis that the biliary excretion of organic anions is pre-
dominantly mediated by cMOAT/MRP2 in rats, whereas the
contribution of MRP3 may be signi¢cant in humans.
The extensive expression of MRP3 in intestine may be re-
lated to the intestinal excretion of organic anions. Recently,
using an Ussing chamber, Fujita et al. [39] suggested the pres-
ence of an active transport system for calcein on the brush
border membrane of intestinal epithelium. However, by com-
paring the disposition of 1-naphthol glucuronide between nor-
mal and TR3 rats, it has been suggested that cMOAT/MRP2
may not be responsible for the intestinal excretion of this
conjugated metabolite [40]. Moreover, Caco-2 cells can ex-
trude 2P,7P-bis(2-carboxyethyl)-5(6)-carboxy£uorescein and
2,4-dinitrophenyl S-glutathione across both membranes in
an ATP-dependent manner [41,42]. Together with the expres-
sion of MRP3 in Caco-2 cells, it is possible that MRP3 might
be involved in the intestinal transport of organic anions.
In conclusion, we cloned cDNA encoding the full length of
human MRP3. Expression of MRP3 was induced by PB in
HepG2 cells. Although the function and localization of this
cDNA product remain to be clari¢ed, it is possible that this
inducible transporter may be involved in the biliary and in-
testinal excretion of organic anions in humans.
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